Prognosys Biosciences Prognosys Offering NGS-Based Custom Peptide Assays as Part of Move Toward Proteomics Premium (This story has been updated to correct a description of the company's technology.) Prognosys Biosciences has developed a cDNA-based system for coding customized peptide libraries and has begun offering it commercially as a research tool. Downloads and Upgrades: Enzyme Portal; CIRO+ Data Center; BioCyc 16.0; and more Premium The European Bioinformatics Institute has launched the Enzyme Portal, a free resource for researchers studying the biology of enzymes and proteins with enzymatic activity. Prognosys Biosciences Looks for Edge in NGS Analysis Market with Cloud Platform for RNA-Seq Premium By Uduak Grace Thomas Febit Plans to Launch HybSelect App in March in Bid to Tap Seq-Capture Market Premium Febit plans to debut the method at Cambridge Healthtech Institute's Next-Generation Sequencing conference in San Diego next month. Breaking News Gastric Cancer Chemotherapy Response, Prognoses Predicted With Blood-Based Immune Proteomics International Commission Formed to Expand Molecular Testing Access to Cancer Patients NYU Langone Perlmutter Cancer Center to Validate Biological Dynamics Pancreatic Cancer Test SomaLogic Expands Into Middle East With Proteomics Supply Deal for Group 42 Healthcare Arima Genomics to Offer NGS-Based Gene Fusion Test Through Protean BioDiagnostics CLIA Lab The Scan Drug Response Variants May Be Distinct in Somatic, Germline Samples Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline. Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine. Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures. Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.